Close Menu

NEW YORK (GenomeWeb) – OncoCyte said after the close of the market on Tuesday that its 2019 Q1 net loss rose about two percent year over year, as the firm nears the launch of its non-invasive lung cancer detection test, DetermaVu.

The liquid biopsy firm's net loss for the three months ended March 31, 2019 was $3.9 million, or $.08 per share, compared to a net loss of $3.8 million, or $.12 per share, in the same quarter last year, slightly beating the consensus Wall Street estimate of a loss of $.09 per share.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.